|
業務類別
|
Biotechnology |
|
業務概覽
|
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier. |
| 公司地址
| 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 415 231-5660 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.alector.com |
| 員工數量
| 103 |
| Mr. Neil Berkley |
Chief Business Officer and Chief Financial Officer |
美元 455.00K |
28/04/2026 |
| Dr. Arnon Rosenthal, PhD |
Director and Chief Executive Officer |
美元 678.10K |
28/04/2026 |
| Ms. Grace Wong-Sarad |
Vice President, Accounting and Principal Accounting Officer |
-- |
25/02/2026 |
|
|
| Mr. Louis J. Lavigne, Jr |
Chairman of the Board |
28/04/2026 |
| Mr. Mark Altmeyer |
Independent Director |
28/04/2026 |
| Dr. Richard H. Scheller, PhD |
Director |
28/04/2026 |
| Dr. Arnon Rosenthal, PhD |
Director and Chief Executive Officer |
28/04/2026 |
| Dr. Kristine Yaffe, M.D. |
Independent Director |
28/04/2026 |
| Dr. Paula Hammond, PhD |
Independent Director |
28/04/2026 |
| Dr. Elizabeth A. Garofalo, M.D. |
Independent Director |
28/04/2026 |
| Dr. Errol B. De Souza,PhD |
Independent Director |
28/04/2026 |
|
|
|
|
